Report Detail
Liquid Biopsy
- RnM3376137 |
- 12 March, 2020 |
- Global |
- 496 Pages |
- IQ4I Research & Consultancy |
- Biotechnology
Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.
According to IQ4I analysis, the liquid biopsy global market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.
The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.
The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.
The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.
The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of $1,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.
The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.
The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)
1 EXECUTIVE SUMMARY 27
2 INTRODUCTION 36
- 2.1 KEY TAKE AWAYS 36
- 2.2 REPORT DESCRIPTION 37
- 2.3 MARKETS COVERED 39
- 2.4 STAKEHOLDERS 41
- 2.5 RESEARCH METHODOLOGY 41
- 2.5.1 MARKET SIZE ESTIMATION 42
- 2.5.2 MARKET CRACKDOWN AND DATATRIANGULATION 45
- 2.5.3 SECONDARY SOURCES 46
- 2.5.4 KEY DATA POINTS FROM SECONDARY SOURCES 47
- 2.5.5 PRIMARY SOURCES 47
- 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 48
- 2.5.7 ASSUMPTIONS 48
3 MARKET ANALYSIS 50
- 3.1 INTRODUCTION 50
- 3.2 MARKET SEGMENTATION 51
- 3.3 FACTORS INFLUENCING MARKET 53
- 3.3.1 DRIVERS AND OPPORTUNITIES 54
- 3.3.1.1 Rising incidence of cancer 54
- 3.3.1.2 increasing preference for blood/urine based liquid biopsy over invasive tissue
biopsy procedures 55
- 3.3.1.3 rising number of late pregnancies leading to high incidence rate of babies with chromosomal disorders 56
- 3.3.1.4 Increasing funding for liquid based test development 57
- 3.3.1.5 Technological advancements in liquid biopsy 57
- 3.3.1.6 Agreements and collaborations 58
- 3.3.1.7 Increasing number of liquid biopsy test launches 59
- 3.3.1 DRIVERS AND OPPORTUNITIES 54
- 3.3.2 RESTRAINTS AND THREATS 60
- 3.3.2.1 High cost with less reimbursement facilities 60
- 3.3.2.2 Ethical issues related to genetic testing 60
- 3.3.2.3 Lack of skilled healthcare professionals 61
- 3.3.2.4 Lack of standardization of liquid biopsy tests 61
- 3.3.2.5 Regulatory issues 62
- 3.4.1 U.S. 63
- 3.4.2 EUROPE 63
- 3.4.3 CHINA 64
- 3.4.4 INDIA 65
- 3.4.5 JAPAN 65
- 3.5.1 THREAT OF NEW ENTRANTS 67
- 3.5.2 THREAT OF SUBSTITUTES 67
- 3.5.3 COMPETITIVE RIVALRY 67
- 3.5.4 BARGAINING POWER OF SUPPLIERS 68
- 3.5.5 BARGAINING POWER OF BUYERS 69
- 3.10.1 MICRORNA (MIRNA) 97
- 3.10.2 PROTEIN BIOMARKERS 98
- 3.10.3 CIRCULATING MRNA 98
- 3.10.4 CRISPR PAPER TEST (SHERLOCK) 98
4 MARKET SIZING 126
- 4.1 U.S.LIQUID BIOPSY MARKET SIZING INFORMATION 126
- 4.1.1 ONCOLOGY TESTING 127
- 4.1.1.1 Early screening 127
- 4.1.1.2 Companion diagnostics 127
- 4.1.1.3 Prognosis monitoring 129
- 4.1.1.4 Recurrence monitoring 130
- 4.1.2 NON-INVASIVE PRENATAL SCREENING (NIPT) 131
- 4.1.3 TRANSPLANTATION DIAGNOSTICS 132
- 4.1.1 ONCOLOGY TESTING 127
5 LIQUID BIOPSY GLOBAL MARKET, BY BIOMARKER 134
- 5.1 INTRODUCTION 134
- 5.2 CIRCULATING TUMOUR CELLS (CTC) 137
- 5.3 CELL-FREE DNA (CFDNA) 141
- 5.4 EXOSOMES & OTHERS 144
6 LIQUID BIOPSY GLOBAL MARKET, BY APPLICATION 149
- 6.1 INTRODUCTION 149
- 6.2 ONCOLOGY TESTING 152
- 6.2.1 CANCER TYPES 154
- 6.2.1.1 Introduction 154
- 6.2.1.2 Lung cancer 159
- 6.2.1.3 Breast cancer 165
- 6.2.1.4 Colorectal cancer 169
- 6.2.1.5 Melanoma 175
- 6.2.1.6 Prostate cancer 177
- 6.2.1.7 Ovarian cancer 182
- 6.2.1.8 Others 184
- 6.2.2 CANCER CARE 190
- 6.2.2.1 Introduction 190
- 6.2.2.2 Early screening 192
- 6.2.2.3 Companion diagnosis 195
- 6.2.2.4 Prognosis monitoring 197
- 6.2.2.5 Recurrence monitoring 200
- 6.2.1 CANCER TYPES 154
- 6.3 PRENATAL TESTING 203
- 6.4 TRANSPLANTATION 206
7 LIQUID BIOPSY GLOBAL MARKET, BY SAMPLE 209
- 7.1 INTRODUCTION 209
- 7.2 BLOOD 211
- 7.3 URINE AND OTHERS 215
8 LIQUID BIOPSY GLOBAL MARKET, BY END-USERS 219
- 8.1 INTRODUCTION 219
- 8.2 HOSPITALS 222
- 8.3 ACADEMIC & RESEARCH INSTITUTES 225
9 REGIONAL ANALYSIS 229
- 9.1 INTRODUCTION 229
- 9.2 NORTH AMERICA 232
- 9.2.1 UNITED STATES 246
- 9.2.2 OTHERS 250
- 9.3 EUROPE 254
- 9.3.1 GERMANY 268
- 9.3.2 FRANCE 272
- 9.3.3 U.K. 276
- 9.3.4 OTHERS 280
- 9.4 ASIA-PACIFIC 284
- 9.4.1 JAPAN 298
- 9.4.2 CHINA 302
- 9.4.3 INDIA 306
- 9.4.4 OTHERS 310
- 9.5 REST OF THE WORLD (ROW) 314
- 9.5.1 BRAZIL 328
- 9.5.2 REST OF LATIN AMERICA 332
- 9.5.3 MIDDLE EAST & OTHERS 336
10 COMPETITIVE LANDSCAPE 340
- 10.1 INTRODUCTION 340
- 10.2 AGREEMENTS 341
- 10.3 COLLABORATIONS/PARTNERSHIPS 354
- 10.4 NEW PRODUCT LAUNCHES 362
- 10.5 APPROVALS 370
- 10.6 ACQUSTIONS 372
- 10.7 OTHERS 374
11 MAJOR COMPANIES 382
- 11.1 BGI (BGI DIAGNOSTICS) 382
- 11.1.1 OVERVIEW 382
- 11.1.2 FINANCIALS 382
- 11.1.3 PRODUCTS NIFTY TEST 382
- 11.1.4 KEY DEVELOPMENTS 383
- 11.1.5 BUSINESS STRATEGY 385
- 11.1.6 SWOT ANALYSIS 386
- 11.2 BIOCEPT, INC. 387
- 11.2.1 OVERVIEW 387
- 11.2.2 FINANCIALS 388
- 11.2.3 PRODUCT PORTFOLIO 388
- 11.2.4 KEY DEVELOPMENTS 389
- 11.2.5 BUSINESS STRATEGY 398
- 11.2.6 SWOT ANALYSIS 399
- 11.3 CAREDX, INC. 400
- 11.3.1 OVERVIEW 400
- 11.3.2 FINANCIALS 401
- 11.3.3 PRODUCT DESCRIPTION 403
- 11.3.4 KEY DEVELOPMENTS 404
- 11.3.5 BUSINESS STRATEGY 406
- 11.3.6 SWOT ANALYSIS 407
- 11.4 CYNVENIO BIOSYSTEMS, INC 408
- 11.4.1 OVERVIEW 408
- 11.4.2 FINANCIALS 408
- 11.4.3 PRODUCT PORTFOLIO 409
- 11.4.4 KEY DEVELOPMENTS 409
- 11.4.5 BUSINESS STRATEGY 413
- 11.4.6 SWOT ANALYSIS 414
- 11.5 EUROFINS SCIENTIFIC SE (LIFECODEXX) 415
- 11.5.1 OVERVIEW 415
- 11.5.2 FINANCIALS 416
- 11.5.3 PRODUCT PORTFOLIO 417
- 11.5.4 KEY DEVELOPMENTS 418
- 11.5.5 BUSINESS STRATEGY 420
- 11.5.6 SWOT ANALYSIS 421
- 11.6 EXACT SCIENCES CORPORATION 422
- 11.6.1 OVERVIEW 422
- 11.6.2 FINANCIALS 423
- 11.6.3 PRODUCT PORTFOLIO 423
- 11.6.4 KEY DEVELOPMENTS 424
- 11.6.5 BUSINESS STRATEGY 425
- 11.6.6 SWOT ANALYSIS 426
- 11.7 EXOSOME DIAGNOSTICS, INC 427
- 11.7.1 OVERVIEW 427
- 11.7.2 FINANCIALS 427
- 11.7.3 PRODUCT PORTFOLIO 428
- 11.7.4 KEY DEVELOPMENTS 428
- 11.7.5 BUSINESS STRATEGY 432
- 11.7.6 SWOT ANALYSIS 433
- 11.8 GUARDANT HEALTH, INC. 434
- 11.8.1 OVERVIEW 434
- 11.8.2 FINANCIALS 434
- 11.8.3 PRODUCT DESCRIPTION 434
- 11.8.4 KEY DEVELOPMENTS 435
- 11.8.5 BUSINESS STRATEGY 441
- 11.8.6 SWOT ANALYSIS 442
- 11.9 ILLUMINA, INC. 443
- 11.9.1 OVERVIEW 443
- 11.9.2 FINANCIALS 444
- 11.9.3 PRODUCT PORTFOLIO 446
- 11.9.4 KEY DEVELOPMENTS 447
- 11.9.5 BUSINESS STRATEGY 448
- 11.9.6 SWOT ANALYSIS 449
- 11.10 IMMUCOR 450
- 11.10.1 OVERVIEW 450
- 11.10.2 FINANCIALS 451
- 11.10.3 PRODUCT PORTFOLIO 453
- 11.10.4 KEY DEVELOPMENTS 454
- 11.10.5 BUSINESS STRATEGY 454
- 11.10.6 SWOT ANALYSIS 455
- 11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS 456
- 11.11.1 OVERVIEW 456
- 11.11.2 FINANCIALS 457
- 11.11.3 PRODUCT PORTFOLIO 459
- 11.11.4 KEY DEVELOPMENTS 460
- 11.11.5 BUSINESS STRATEGY 461
- 11.11.6 SWOT ANALYSIS 462
- 11.12 MDX HEALTH 463
- 11.12.1 OVERVIEW 463
- 11.12.2 FINANCIALS 464
- 11.12.3 PRODUCT DESCRIPTION 464
- 11.12.4 KEY DEVELOPMENTS 465
- 11.12.5 BUSINESS STRATEGY 470
- 11.12.6 SWOT ANALYSIS 471
- 11.13 MYRIAD GENETICS, INC. 472
- 11.13.1 OVERVIEW 472
- 11.13.2 FINANCIALS 473
- 11.13.3 PRODUCT PORTFOLIO 474
- 11.13.4 KEY DEVELOPMENTS 476
- 11.13.5 BUSINESS STRATEGY 478
- 11.13.6 SWOT ANALYSIS 479
- 11.14 NATERA, INC. 480
- 11.14.1 OVERVIEW 480
- 11.14.2 FINANCIALS 481
- 11.14.3 PRODUCT PORTFOLIO 482
- 11.14.3.1 PANORAMA 482
- 11.14.3.2 CONSTELLATION 483
- 11.14.3.3 SIGNATERA 483
- 11.14.3.4 VISTARA 483
- 11.14.4 KEY DEVELOPMENTS 483
- 11.14.5 BUSINESS STRATEGY 485
- 11.14.6 SWOT ANALYSIS 487
- 11.15 ROCHE HOLDINGS AG 488
- 11.15.1 OVERVIEW 488
- 11.15.2 FINANCIALS 489
- 11.15.3 PRODUCT DESCRIPTION 493
- 11.15.4 KEY DEVELOPMENTS 493
- 11.15.5 BUSINESS STRATEGY 494
Summary:
Get latest Market Research Reports on Liquid Biopsy . Industry analysis & Market Report on Liquid Biopsy is a syndicated market report, published as Liquid Biopsy . It is complete Research Study and Industry Analysis of Liquid Biopsy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
